Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
This is an prospective, multicenter, single-arm clinical study.
Trial Details
- NCT ID
- NCT05525767
- Phase
- PHASE4
- Sponsor
- Hebei Medical University Fourth Hospital
- Status
- RECRUITING
- Cancer Type
- Breast Cancer
- Locations (sample)
- Shijiazhuang, Hebei, China
Key Eligibility Criteria
- Age ≥18 years old;
- Signed the informed consent and volunteered to join the study with good compliance;
- 3, histopathologically confirmed HER2-negative invasive breast cancer (including triple-negative breast cancer; Or Luminal breast cancer, that is, …
- HER2 negative was defined as 0/1+ on standard IHC test; HER2/CEP17 ratio was less than 2.0 or HER2 gene copy number was less than 4.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →